| Arrhythmic risk stratification of post-myocardial infarction patients. | |
| | |
MedLine Citation:
|
PMID: 10666655 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Post-myocardial infarction risk stratification, especially arrhythmic risk stratification, is an issue that has still not been wholly addressed in modern clinical cardiology. In the past 10 years, arrhythmic risk stratification has been approached mainly by evaluating frequency and complexity of premature ventricular contractions, detected on Holter monitoring, often in association with determination of percent ejection fraction. This methodology has been proven to be limited and fallacious according to the Cardiac Arrhythmia Suppression Trial I and II (CAST I,II) results, in which suppression of premature ventricular contractions or premature ventricular beats throughout by antiarrhythmic drugs resulted in an increase in both cardiac and arrhythmic mortality. Only amiodarone as an antiarrhythmic drug, as proven in the recent European Myocardial Infarct Amiodarone Trial (EMIAT) and Canadian Amiodarone Myocardial Infarction Trial (CAMIAT), was effective in reducing arrhythmic mortality without affecting cardiac mortality, in patients selected mainly because of a reduced ejection fraction, with and without premature ventricular contractions. Conversely, it is well known that beta-blockers are effective in preventing sudden death in post-acute myocardial infarction (AMI) patients, thus reducing cardiac and arrhythmic mortality. Conversely, in other institutions, risk stratification in post-AMI patients has been performed by electrophysiologic study obtained, without any previous noninvasive arrhythmic risk stratification, in all post-AMI patients. In recent years, many other noninvasive electrocardiology parameters, such as late potentials (signal-averaged electrocardiography), heart rate variability, baroreflex sensitivity, and, more recently, T-wave alternance, have been shown to be useful, but they are associated with a low specificity in the noninvasive identification of patients at high risk for arrhythmic mortality. Conversely, in the Multicenter Automatic Defibrillation Implantation Trial (MADIT), electrophysiology confirmed that inducibility of ventricular tachycardia shows high specificity and a high predictive value for arrhythmic events. Nevertheless, the MADIT study population is not comparable to a cohort of consecutive patients who have recently had a myocardial infarction. In this setting, the highest risk of arrhythmic events can be observed in patients with depressed percent ejection fraction (< 35%) and in the first 6 months after AMI. Today, the most convincing approach seems to be the one combining both noninvasive risk stratification parameters (e.g., premature ventricular beats > 10/h or reduced heart rate variability < 70 ms or a positive signal-averaged electrocardiogram) followed by a further arrhythmic risk stratification, obtained through electrophysiologic study. Several published and ongoing trials that utilize various arrhythmic risk stratification techniques as part of their protocol are reviewed. |
| | |
Authors:
|
F Naccarella; G Lepera; A Rolli |
Related Documents
:
|
23540585 - Heart failure therapy in patients with coronary artery disease. 14499225 - Cost of strategies after myocardial infarction (costami): a multicentre, international,... 8403305 - Predicting early and intermediate-term outcome of coronary angioplasty in the elderly. 8427125 - Variables associated with a poor prognosis in patients with an ischemic thallium-201 ex... 20187175 - Improved arterial spin labeling after myocardial infarction in mice using cardiac and r... 3904535 - The clinical spectrum of tricuspid regurgitation detected by pulsed doppler echocardiog... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current opinion in cardiology Volume: 15 ISSN: 0268-4705 ISO Abbreviation: Curr. Opin. Cardiol. Publication Date: 2000 Jan |
Date Detail:
|
Created Date: 2000-02-24 Completed Date: 2000-02-24 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8608087 Medline TA: Curr Opin Cardiol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1-6 Citation Subset: IM |
Affiliation:
|
Dipartimento di Cardiologia, Azienda Sanitaria della Cittá di Bologna, Italy. wnacca@tin.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Amiodarone
/
therapeutic use Anti-Arrhythmia Agents / therapeutic use Arrhythmias, Cardiac / diagnosis, etiology, mortality* Death, Sudden, Cardiac / etiology, prevention & control Electrophysiology Humans Myocardial Infarction / complications*, drug therapy, mortality Risk Factors |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Arrhythmia Agents; 1951-25-3/Amiodarone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Perioperative lower urinary tract infections and deep sepsis in patients undergoing total joint arth...
Next Document: Inpatient versus outpatient antiarrhythmic drug initiation: safety and cost-effectiveness issues.